The risk for inflammatory bowel disease is higher in patients with psoriasis or ankylosing spondylitis using IL-17A inhibitors than in those using apremilast, necessitating careful patient monitoring.

In patients with significant psoriasis, an interleukin (IL)-17 inhibitor may be preferred ... Manifestations of IBD include ...

This has given rise to a new generation of selective IL-23p19 inhibitors, a class that is rapidly reshaping IBD treatment. This article delves into the three approved assets in this class ...

IBD is a chronic condition characterized by inflammation ... SPY003 demonstrated equivalent potency to risankizumab in inhibiting pSTAT signaling and IL-17 production and exhibited significantly ...